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ARTICLE

Mechanical dysfunction of the sarcomere induced by
a pathogenic mutation in troponin T drives
cellular adaptation
Familial hypertrophic cardiomyopathy (HCM), a leading cause of sudden cardiac death, is primarily caused by mutations in
sarcomeric proteins. The pathogenesis of HCM is complex, with functional changes that span scales, from molecules to tissues.
This makes it challenging to deconvolve the biophysical molecular defect that drives the disease pathogenesis from
downstream changes in cellular function. In this study, we examine an HCM mutation in troponin T, R92Q, for which several
models explaining its effects in disease have been put forward. We demonstrate that the primary molecular insult driving
disease pathogenesis is mutation-induced alterations in tropomyosin positioning, which causes increased molecular and
cellular force generation during calcium-based activation. Computational modeling shows that the increased cellular force is
consistent with the molecular mechanism. These changes in cellular contractility cause downstream alterations in gene
expression, calcium handling, and electrophysiology. Taken together, our results demonstrate that molecularly driven
changes in mechanical tension drive the early disease pathogenesis of familial HCM, leading to activation of adaptive
mechanobiological signaling pathways.

Introduction
Hypertrophic cardiomyopathy (HCM) is the leading cause of
sudden cardiac death in people younger than 30 yr. HCM is
characterized by hypertrophy of the left ventricular wall and
interventricular septum, myocyte disarray, fibrosis, and diastolic
dysfunction. HCM is also associated with marked alterations in
cardiomyocyte function, including changes in electrophysiology,
contractility, and calcium handling (Harvey and Leinwand,
2011). Large-scale sequencing of families has revealed that
HCM is caused by mutations in sarcomeric proteins involved
in cardiac contraction, including troponin T (Watkins et al.,
1995).
The disease presentation in HCM is quite complex, with
functional differences seen at scales ranging from molecules to
tissues; however, the molecular triggers that drive the disease
pathogenesis are alterations in the abundance, stability, and/or
functionality of mutant protein (Greenberg and Tardiff, 2021).
This initial trigger activates downstream adaptive and maladaptive processes, some of which can take years to decades to
manifest, including ventricular remodeling, and eventually

symptomatic disease. Given the inherent complexity of HCM, it
has been challenging to link the molecular and cellular phenotypes and to dissect the initial biophysical trigger from secondary adaptive processes.
To better understand the initial molecular insult and its
connection to cellular dysfunction in early HCM disease pathogenesis, we examined a pathogenic mutation in troponin T,
R92Q (Fig. 1 A), identified in several unrelated families, that
causes pronounced ventricular hypertrophy and a relatively
high incidence of sudden cardiac death (Watkins et al., 1995).
R92Q has been studied in model systems, including feline
(Marian et al., 1997) and rat (Rust et al., 1999) cardiomyocytes,
rabbit skeletal myofibrils (Morimoto et al., 1998), quail myotubes (Sweeney et al., 1998), and transgenic mice (Tardiff et al.,
1999). These studies have reached conflicting conclusions about
the effects of the mutation, in part due to phenotypic differences
between species. For example, the widely studied transgenic
mouse model of R92Q (Tardiff et al., 1999) recapitulates some,
but not all, aspects of the human disease phenotype. Elegant
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experiments by the Tardiff laboratory showed that the disease
presentation in mice depends on the myosin heavy chain isoform expressed, with different phenotypes seen when using the
faster (MYH6) isoform found in mouse ventricles or the slower
(MYH7) isoform found in human ventricles (Ford et al., 2012).
This highlights the need to study the mutation in humanized
systems.
Troponin T is part of the troponin complex, which, together
with tropomyosin, regulates the calcium-dependent interactions
between myosin and the thin filament that power muscle contraction. Biochemical (McKillop and Geeves, 1993) and structural
(Lehman et al., 1994) measurements demonstrated that tropomyosin can lie in three states along the thin filament (Fig. 1 B). In
the absence of calcium, tropomyosin lies in the blocked position
and inhibits the binding of force-generating actomyosin crossbridges. When calcium binds to troponin C, tropomyosin shifts
to the closed position. The tropomyosin can then be pushed into
the open position by either thermal fluctuations or myosin weak
binding. Once weakly associated with the thin filament, myosin
isomerizes into the strong binding state, generating force. The
amount of force developed will be proportional to the number of
strongly bound, force-generating myosin cross-bridges.
Three models have been put forward to describe the initial
molecular insult that drives the R92Q disease pathogenesis
(Fig. 1 B): (1) R92Q could affect the cycling kinetics of myosins
bound to the thin filament (Ford et al., 2012); (2) R92Q could
Clippinger et al.
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increase the calcium affinity of troponin, leading to altered
calcium buffering by myofilaments that directly disrupts calcium homeostasis (Schober et al., 2012; Ferrantini et al., 2017;
Robinson et al., 2018); or (3) R92Q could alter the distribution of
positions assumed by tropomyosin along the thin filament,
changing the number of bound myosin cross-bridges (McConnell
et al., 2017). The mechanistic differences among these models
have important implications for the design of therapeutic
strategies.
Here, we set out to identify the initial molecular insult in
troponin T caused by the R92Q mutation and link the molecular
defect to observed derangements in cellular function. To do this,
we developed a human R92Q model in gene-edited human
induced pluripotent stem cell–derived cardiomyocytes (hiPSCCMs). We show that the initial biophysical insult is altered positioning of tropomyosin along the thin filament, which directly
affects cellular tension, leading to secondary adaptive changes in
calcium homeostasis, gene expression, and electrophysiology.
Our results implicate mechanobiological signaling as a primary
driver of HCM disease pathogenesis.
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Figure 1. R92Q mutation in troponin T causes HCM. (A) Cartoon of the troponin complex (based on Sheng and Jin, 2014). R92Q is located in the region of
troponin T that interacts with tropomyosin, near the tropomyosin overlap region. (B) Models for the molecular mechanism of R92Q.

Materials and methods
Protein modification and purification
Cardiac myosin and actin were purified from cryoground porcine ventricles (Pelfreez) as previously described (Clippinger
Journal of General Physiology
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In vitro motility assays
In vitro motility assays were conducted using thin filaments
containing R92Q troponin T as previously described (Clippinger
et al., 2019). Data for WT troponin T are from Clippinger et al.
(2019). Briefly, enzymatically inactive full-length porcine cardiac myosin was removed by cosedimentation with phalloidinstabilized F-actin in the presence of ATP. Flow cells were loaded
with 1 vol (50 µl) 200 nM myosin, 2 vol 1 mg/ml BSA, 1 vol 1 µM
F-actin, 2 vol KMg25 (25 mM KCl, 4 mM MgCl2, 1 mM EGTA,
1 mM DTT, and 60 mM MOPS, pH 7.0) + 1 mM MgATP, 4 vol
KMg25, and 1 vol 40 nM rhodamine-phalloidin–labeled thin
filaments. After loading 2 vol activation buffer (KMg25 with
4 mM MgATP, 1 mg/ml glucose, 192 U/ml glucose oxidase, 48 µg/
ml catalase, 2 µM troponin and tropomyosin, and 0.5% methyl
cellulose), flow cells were imaged for 20 frames. Each buffer was
balanced to give the desired free calcium, free magnesium, and
ionic strength using MaxChelator (Bers et al., 2010). Individual
motile filaments were manually tracked using the MTrackJ
plugin in Fiji ImageJ (Schindelin et al., 2012), and each point
shows the average and standard deviation of the speed from
three separate experiments.
Stopped-flow transient kinetic measurement of KB and
ADP release
An SX-20 stopped-flow apparatus (Applied Photophysics) was
used. KB, the equilibrium constant between the blocked and
closed states, was determined as previously described (Barrick
et al., 2019; Clippinger et al., 2019). WT data are from Clippinger
et al. (2019). At both low (pCa 9) and high calcium (pCa 4), 5 µM
phalloidin-stabilized pyrene actin, 2 µM tropomyosin, 2 µM
troponin, and 0.04 U/ml apyrase were rapidly mixed with 0.5
Clippinger et al.
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µM S1 myosin and 0.04 U/ml apyrase. Performed at 20°C, each
experiment was the average of at least three separate mixes, and
the data were fit by a single exponential curve. KB was calculated
from
kobs (−Ca2+ )
KB
.

2+
1
+
KB
kobs (+Ca )

(1)

The reported KB is the average of at least three different experiments. The P value was calculated from a two-tailed Student’s t test.
The rate of ADP release from myosin bound to regulated thin
filaments (20°C) was measured as previously described. (Clippinger
et al., 2019) The average and standard deviation of the rate of at least
four experiments was calculated and the P value was derived using
a two-tailed Student’s t test.
Fluorescence titrations to measure KW, KT, and n
A SX-20 stopped-flow fluorometer was used for all fluorescence
titrations. The values of KW (the equilibrium constant for myosin weak binding), KT (the equilibrium constant between the
closed and open states), and n (the cooperativity) were determined for R92Q and WT using fluorescence titrations as previously described (Barrick et al., 2019; Clippinger et al., 2019). The
WT data are from Clippinger et al. (2019). Hypothesis testing
and uncertainty estimation were done using established techniques (Efron, 1979; Press, 1992; Martin, 2007). Briefly, the data
were resampled using a bootstrapping algorithm, resampled
data were fit to calculate 95% confidence intervals, and P values
were calculated from the overlap regions between the distributions of bootstraps (Efron, 1979; Press, 1992; Martin, 2007;
Barrick et al., 2019).
Measurement of calcium binding to troponin C
The calcium affinity for the troponin complex (TnIAANS) was
determined by titrating regulated thin filaments with increasing
calcium concentrations and measuring the change in fluorescence in IAANS-labeled troponin C upon calcium binding (Davis
et al., 2007). TnIAANS was excited at 330 nm and fluorescence
emission was detected using a 395 nm long-pass filter. 0.15 µM
TnIAANS complex, 0.45 µM tropomyosin, and 2 µM actin were
mixed with increasing concentrations of calcium in 10 mM
MOPS, pH 7.0, 150 mM KCl, 3 mM MgCl2, and 1 mM DTT. Each
buffer was balanced to give the desired free calcium, free
magnesium, and ionic strengths using MaxChelator (Bers et al.,
2010). The solution was allowed to equilibrate for 1 min after
mixing with constant stirring before the fluorescence intensity
was measured. The titration curve was fit by the logistic sigmoid
function, which is mathematically equivalent to the Hill
equation:
Y  Ymin +

Ymax − Ymin
,
1 + exp[(−H(X − pCa50 )]
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et al., 2019). S1 myosin was prepared by chymotrypsin digestion
as previously described (Clippinger et al., 2019). Recombinant
human cardiac tropomyosin, troponin I, troponin T, and troponin C were expressed in Escherichia coli and purified from BL21CodonPlus cells (Agilent) as described previously (Clippinger
et al., 2019). Purified tropomyosin was reduced in 50 mM dithiothreitol (DTT) at 56°C for 5 min and ultracentrifuged to
remove aggregates immediately before being used in each
assay. The R92Q mutation was introduced into troponin T
using QuickChange Site-Directed Mutagenesis (Agilent), and
the presence of the mutation was verified by sequencing.
For the studies of calcium binding, we used IAANS (6-((4-((2iodoacetyl)amino)phenyl)amino)-2-naphthalenesulfonic acid)–
labeled troponin C (Davis et al., 2007). IAANS was custom
synthesized by Toronto Research Chemicals. Troponin CT53C
was labeled with fivefold molar excess IAANS dye overnight,
and the reaction was quenched with DTT. Excess dye was
dialyzed out with four dialysis buffer changes of 1 mM DTT,
0.01% NaN3, 50 µM CaCl2, 1 mM MgCl2, 3 M urea, 1 M KCl,
5 mg/liter tosyl phenylalanyl chloromethyl ketone (TPCK),
5 mg/liter tosyl-L-lysyl-chloromethane hydrochloride
(TLCK), and 0.3 mM PMSF (Davis et al., 2007). The IAANSlabeled troponin CT53C was then purified over a MonoQ column and complexed with troponins T and I as done previously
(Clippinger et al., 2019).

(2)

where Ymax and Ymin are the maximum and minimum IAANS
fluorescence, X is the negative logarithm of [Ca2+]free, pCa50 is
the negative log of the concentration of free calcium producing
half-maximal fluorescence, and H is the cooperativity (proportional to the Hill coefficient; Tikunova et al., 2002). Titrations
Journal of General Physiology
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were performed at both 15°C and 20°C to facilitate comparison
with previous measurements using different proteins (Liu et al.,
2012). For the measurements at 37°C (Fig. S1), we used a Horiba
fluorometer. We excited the fluorophore at 330 nm and integrated the fluorescence >500 nm (Davis et al., 2007). Data were
analyzed with the same methodology.

Stem cell line derivation
R92Q stem cells were derived and the quality control was performed using procedures described in depth previously
(Clippinger et al., 2019). Briefly, the parent human BJ fibroblast
stem cell line (ATCC; BJFF.6) was reprogrammed to stem cells
by the Genome Engineering and iPSC Center (GEiC) at Washington University in St. Louis. Two independent isogenic stem
cell lines with the R92Q hTNNT2 point mutation were also
generated at the GEiC using the CRISPR-Cas9 system (Jinek et
al., 2012; Fig. S2). The oligo used to generate the guide RNA
(gRNA) was 59-CCTTCTCCATGCGCTTCCGGNGG-39, and the
mutation was introduced by homology-directed repair. This
gRNA was selected to minimize off-target effects. The presence of the homozygous mutation was verified by sequencing.
Karyotype (G-banding) analysis was performed by Cell Line
Genetics (Fig. S2). Mycoplasma testing and immunofluorescence staining for pluripotency markers were performed by
the GEiC (Fig. S3).
Stem cell and hiPSC-CMs culture
Stem cell culture and differentiation to hiPSC-CMs were done as
previously described (Clippinger et al., 2019). Briefly, stem cells
were maintained in feeder-free culture. To differentiate the
stem cells to hiPSC-CMs, we used small-molecule manipulation
of WNT signaling (Lian et al., 2012; Lian et al., 2013). hiPSC-CMs
were enriched using metabolic selection (Sharma et al., 2015).
All functional experiments were conducted at least 30 d after the
Clippinger et al.
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Microcontact patterning of hiPSC-CMs on glass and hydrogels
Fabrication of rectangular (7:1 aspect ratio) polydimethylsiloxane
stamps for micropatterning of hiPSC-CMs on both glass and 10kPa hydrogels was done as previously described (Ribeiro et al.,
2015; Clippinger et al., 2019). Cells were patterned onto 10-kPa
polyacrylamide hydrogels containing stamped Geltrex (Thermo
Fisher Scientific) in rectangular patterns as reported previously
(Clippinger et al., 2019; Fig. S3).
Quantification of troponin I isoform expression by
Western blotting
Cell lysates from multiple differentiations were extracted from
wild type and mutant hiPSC-CMs using protein lysis buffer
containing 20 mM HEPES, pH 7.0, 150 mM NaCl, 0.5% 3-(3cholamidopropyl)diethylammonio-1 propanesulfonate, and one
protease inhibitor cocktail tablet (Roche complete mini EDTAfree tablets). 30 µg of each protein lysate was loaded per well of
an Any kD Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad),
separated by electrophoresis, and transferred to polyvinylidene
difluoride membranes (Sigma). Membranes were blocked with 5%
milk and incubated overnight with primary antibodies. One
membrane was incubated with mouse anti-GAPDH antibody
(DSHB; DSHB-hGAPDH-2G7; 3 µg/ml) and mouse anti-slow skeletal troponin I antibody (Santa Cruz Biotechnology; sc-514899; 1:
700). The other membrane was incubated with mouse antiGAPDH antibody (DSHB; DSHB-hGAPDH-2G7; 3 µg/ml) and rabbit anti-cardiac troponin I (Santa Cruz Biotechnology; sc-15368; 1:
500). After washing off the primary antibodies, the membranes
were incubated with anti-rabbit IgG, HRP-linked antibody (Cell
Signaling; 7074S; 1:2,000) and/or anti-mouse IgG, HRP-linked
antibody (Cell Signaling; 7076S; 1:2,000). The proteins were detected using the SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific) and imaged on a MyECL Imager
(Thermo Fisher Scientific). Blot intensity was quantified by densitometry using ImageJ (Schindelin et al., 2012; Fig. S4). P values
were calculated using a Mann–Whitney U test.
Traction force microscopy
Traction force microscopy was conducted on 10-kPa hydrogels
with cells patterned on rectangular patterns as previously described (Clippinger et al., 2019) and analyzed using the computational tool developed in Ribeiro et al., 2017. Data were
analyzed, and 95% confidence intervals of the mean were calculated as described previously (Barrick et al., 2019; Clippinger
et al., 2019). Briefly, the data were resampled using a bootstrapping algorithm to calculate 95% confidence intervals, and P
values were calculated from the overlap regions between the
distributions of bootstraps (Efron, 1979; Press, 1992; Martin,
2007; Barrick et al., 2019). Videos of contracting cells (Video 1)
and sample traces derived from those videos (Fig. S5) are provided. Two independently derived cell lines were examined
(Fig. S6).
Journal of General Physiology
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Computational modeling of sarcomeric contractility
To simulate the effects of the experimentally determined
changes in equilibrium constants on force production, we used
the computational model developed by Campbell et al. (2010),
based on McKillop and Geeves (1993), as we have done previously
(Clippinger et al., 2019). Briefly, in this model, nine sarcomeres are
simulated, where the equilibrium constants between states and a
coupling constant describing cooperativity define the probability of switching between biochemical states. The steadystate force is calculated from the equilibrium distribution of
states at a given calcium concentration. Our biochemical experiments demonstrated that the primary change at the molecular scale with the mutation is an increase in KB, such that
KB (R92Q) = 2.56 × KB (WT). To simulate the WT, we used the
default model parameters. To simulate the mutant, we decreased the reverse rate constant that defines KB, so that KB
(R92Q) = 2.56 × KB (WT). To simulate the force per sarcomere
in response to a calcium transient for the WT, we used the
default calcium transient. To simulate the response of R92Q,
we changed KB as described above and we reduced the amplitude of the default calcium transient to 67% of its value to
match our measurements in hiPSC-CMs.

initiation of differentiation. Experiments were conducted using
two independently derived cell lines for the R92Q mutant. All
experiments were repeated using at least two independent
differentiations.
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Analysis of calcium transients
The calcium transient fluorescence counts were converted to
ratios using Fiji software (Schindelin et al., 2012). The averaged
background fluorescence was subtracted from each recording
and a montage was created from the image stacks. The ratio of
fluorescence at 405 nm/488 nm was then calculated in Excel.
The resulting ratiometric calcium fluorescence traces were then
analyzed using a custom MATLAB script to calculate the amplitude of the calcium transient. Traces with fewer than three
peaks were not analyzed. Briefly, the data were smoothed over a
100-point sliding window using a Savitsky–Golay filter. The
locations of peaks and minima in the fluorescence signal were
determined using a peak-finding algorithm. Statistical significance was tested using a two-tailed Student’s t test.
Measurement of the expression of transcripts encoding key
calcium-handling proteins
hiPSC-CMs were grown on Matrigel-coated (Corning) 10-kPa PrimeCoat elastic substrate culture dishes (ExCellness Biotech; 35 mm)
for 10 d. Total RNA was isolated using RNeasy Mini Kit (Qiagen)
with on-column DNase I treatment according to the manufacturer’s
instructions. cDNA was generated using iScript Reverse Transcription Supermix (Bio-Rad) according to the manufacturer’s instructions. Quantitative PCR (qPCR) reactions were performed in
triplicate using iTaq Universal SYBRGreen Supermix (Bio-Rad) and
the ViiA 7 System (Applied Biosystems). Primers for all genes were
obtained from IDT PrimeTime qPCR primers. Primer product
numbers from IDT are listed in Table S1. Three separate biological
samples were evaluated for both WT and R92Q homozygous hiPSCCMs. The relative levels of mRNA were calculated using the comparative threshold cycle (ΔCt) method (Livak and Schmittgen,
2001). GAPDH and HPRT1 were used as endogenous controls, and
Rox dye present in the master mix was used to normalize
Clippinger et al.
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background fluorescence. ΔCt values are presented in Table S2. The
statistical significance of differences in ΔCt values was evaluated
using a Mann–Whitney U test.
Cellular electrophysiological studies
Whole-cell current- and voltage-clamp recordings were obtained at room temperature (∼22–24°C) from hiPSC-CMs plated
on hydrogel-coated coverslips using a Dagan 3900A (Dagan
Corporation) amplifier interfaced to a Digidata 1332A A/D converter (Axon) and the pClamp 10.3 software (Axon). For currentclamp recordings, recording pipettes contained 135 mM KCl,
5 mM K2ATP, 10 mM EGTA, 10 mM HEPES, and 5 mM glucose
(pH 7.2; 310 mOsm). The bath solution contained 136 mM NaCl,
4 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, and 10 mM
glucose (pH 7.4; 300 mOsm). For recordings of voltage-gated
Ca2+ currents (ICa), pipettes contained 5 mM NaCl, 90 mM Cs
CH3SO3, 20 mM CsCl, 4 mM MgATP, 0.4 mM Tris-GTP, 10 mM
EGTA, 10 mM HEPES, and 3 mM CaCl2 (pH 7.2; 310 mOsm), and
the bath solution contained 20 mM NaCl, 110 mM TEA-Cl,
10 mM CsCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, and
10 mM glucose (pH 7.4; 300 mOsm). In all experiments, pipette
resistances were 2–3 MΩ.
Electrophysiological data were acquired at 10 or 100 kHz, and
signals were low pass filtered at 5 kHz before digitization and
storage. After the formation of a gigaohm seal (>1GΩ) and establishment of the whole-cell configuration, brief (10 ms) ±5-mV
voltage steps from a holding potential (HP) of −70 mV were presented to allow measurements of whole-cell membrane capacitance
(Cm), input resistance (Rin), and series resistance (Rs). Mean ± SEM
Cm values were 32 ± 2 pF and 47 ± 2 pF (P < 0.001) in WT (n = 96)
and R92Q (n = 67) hiPSC-CMs, respectively. Rin values were 1,665 ±
125 MΩ and 1,551 ± 162 MΩ (P > 0.05) in WT (n = 96) and R92Q (n =
67) hiPSC-CMs, respectively. Whole-cell Cm and Rs values were
electronically compensated by 85%. Voltage errors resulting from
the uncompensated Rs were always <2 mV and were not corrected.
Leak currents were always <50 pA and also were not corrected.
In current-clamp recordings, spontaneous action potentials were
recorded on establishing the whole-cell configuration. To record
evoked action potentials, small (approximately −10 to −100 pA)
current injections were made to hyperpolarize the membrane potential to −80 mV and to stop spontaneous firing. Individual action
potentials were then evoked by brief (4 ms) depolarizing current
(600 pA) injections. In voltage-clamp experiments, whole-cell ICa,
evoked in response to depolarizing (300 ms) voltage steps to test
potentials between −45 and +15 mV (in 5-mV increments at 1-s
intervals) from a HP of −50 mV, were recorded.
Analysis of electrophysiological data
Electrophysiological data were compiled and analyzed using
Clampfit 10.3 (Axon) and GraphPad (Prism). Cm values were
determined by integration of the capacitive transients recorded
during ±5-mV voltage steps from −70 mV. Current amplitudes in
each cell were normalized to the Cm, and current densities are
reported (pA/pF). All data are presented as means ± SEM. The
statistical significance of observed differences between WT and
R92Q hiPSC-CMs was evaluated using two-tailed Student’s t test
or two-way ANOVA; P values are presented in Table S3.
Journal of General Physiology
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Measurement of calcium transients in live cells
Live-cell imaging was conducted using the ratiometric fluorescent calcium indicator dye Fura Red AM (Thermo Fisher Scientific). The use of a ratiometric dye is important since the
mutation could affect the uptake of dye into the cells, and the
ratiometric dye normalizes the calcium-induced changes in
fluorescence to the total amount of dye taken up by the cell.
hiPSC-CMs were patterned on hydrogels as described above.
After 5–7 d on the patterns, the cells were loaded with 10 µM
Fura Red AM dye and 0.01% Pluronic F-127 (Invitrogen/Thermo
Fisher Scientific) in RPMI-B27 with insulin media for 20 min at
room temperature. The cells were washed twice and incubated
with Tyrode’s solution (1.8 mM CaCl2, 135 mM NaCl, 4 mM KCl,
1 mM MgCl2, 5 mM glucose, and 10 mM HEPES, pH 7) for
15–20 min at 37°C to allow de-esterification of the dye. Calcium
transients were recorded with a Nikon A1Rsi confocal microscope in line scan mode using a 40× objective and the Ex2Em1
microscope setting. Fura Red AM loaded cells were excited at
both 405 nm and 488 nm, and the emission fluorescence signal
was collected at 595 nm. Line scans were acquired at a sampling
rate of 512 pixels × 1.9 ms per line (total 10,000 lines per recording). Each cell was recorded along with a line scan of the
background fluorescence outside the cell area.
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Results
Determination of the molecular mechanism of R92Q
At the molecular scale, the initial insult that drives the disease
pathogenesis is mutation-induced alterations in protein function. Therefore, we set out to determine the molecular mechanism of the R92Q mutation in troponin T. WT and R92Q human
troponin T were expressed and reconstituted into functional
troponin complexes for biochemical and biophysical measurements. All assays were conducted using recombinant human
tropomyosin and troponin complex. β-Cardiac ventricular myosin (MYH7) and cardiac actin were purified from porcine
hearts. The porcine β-cardiac myosin isoform has 98% sequence
identity with adult human β-cardiac ventricular myosin and similar
biophysical properties, including indistinguishable ATPase kinetics
and mechanics measured in the optical trap (Deacon et al., 2012;
Greenberg et al., 2014; Sung et al., 2015).
We examined the effect of the R92Q mutation on thin filament
regulation using an in vitro motility assay. In this assay, fluorescently labeled reconstituted regulated thin filaments are translocated over a bed of myosin in the presence of ATP and varying
concentrations of calcium. The speed of translocation was measured
as a function of calcium concentration, and normalized data were
fitted with the Hill equation, as previously described (Greenberg
et al., 2010). R92Q-regulated thin filaments show a shift in the pCa50
toward activation at submaximal, but physiologically relevant, calcium concentrations (P < 0.001; Fig. 2 A). There is no change in
cooperativity, as determined by the Hill coefficient (P = 0.76).
The R92Q mutation does not change myosin detachment
kinetics or calcium binding affinity
The shift toward submaximal calcium activation observed for
R92Q in the in vitro motility assay stems from changes in the
function of the troponin T protein. Given the role of troponin T
in regulating calcium-dependent muscle contraction, three
models have been proposed to explain the molecular mechanism
of the R92Q mutation (Fig. 1 B): (1) R92Q could affect the cycling
kinetics of myosins that are bound to the thin filament (Ford
Clippinger et al.
Primary and secondary drivers of an HCM mutation

et al., 2012). In this model, one would expect to observe a change
in the amount of time that myosin remains bound to the thin
filament during cross-bridge cycling in the mutant. (2) R92Q
could increase the calcium affinity of the troponin complex,
leading to altered calcium buffering by myofilaments that directly disrupts calcium homeostasis (Schober et al., 2012;
Ferrantini et al., 2017; Robinson et al., 2018). In this model, one
would expect to observe an increased binding affinity for calcium in the troponin complex containing R92Q. (3) R92Q could
alter the distribution of positions assumed by tropomyosin along
the thin filament, leading to changes in the fraction of bound
myosin cross-bridges (McConnell et al., 2017). In this model, one
would expect to see changes in the equilibrium constants that
define the positioning of tropomyosin along the thin filament.
We set out to test these three models.
First, we tested whether the mutation affects the kinetics of
myosin detachment from the thin filament by using stopped-flow
kinetics to measure the rate of ADP release from actomyosin
(i.e., the transition that limits actomyosin dissociation and unloaded
sliding velocity), as we have done previously (Clippinger et al.,
2019). We found that the rate of ADP release from myosin bound
to regulated thin filaments is not affected by the R92Q mutation (P =
0.88; Fig. 2 B). Therefore, changes in myosin detachment kinetics
cannot explain the shift toward submaximal calcium activation seen
in the in vitro motility assay.
We measured whether the calcium binding affinity to the troponin complex is affected by the mutation. We used an IAANSlabeled form of troponin C to characterize calcium binding to the
troponin complex (Robinson et al., 2007; Liu et al., 2012). The fluorescence intensity of this probe changes upon calcium binding to
troponin C (Davis et al., 2007; Robinson et al., 2007; Liu et al., 2012;
Williams et al., 2016). We used it to spectroscopically measure the
affinity of calcium binding to regulated thin filaments (Fig. 2 C; Liu
et al., 2012). We saw that the calcium concentration required for
half-maximal activation is not significantly different for the WT and
R92Q mutant proteins (P = 0.93). Similar results were seen at 15°C
(Fig. 2 C), 20°C, and 37°C (Fig. S1). These results demonstrate that
changes in the affinity of calcium binding to troponin C cannot
explain the shift toward submaximal calcium activation seen in the
in vitro motility assay (Fig. 2 A). Our finding of no change in calcium affinity for troponin C is consistent with some (Liu et al.,
2012), but not all (Robinson et al., 2007), previous studies. The
difference between our results and those obtained in previous
studies showing changes in calcium affinity could come from differences in the calcium-sensing troponin constructs used, the actin
proteins used (i.e., skeletal [Robinson et al., 2007] versus cardiac in
the present study), or possibly other experimental conditions, such
as the buffer composition.
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Online supplemental material
Fig. S1 shows the affinity of calcium binding to the troponin
complex at 20°C and 37°C. Fig. S2 shows the generation of geneedited hiPSC-CMs. Fig. S3 shows immunofluorescence images of
stem cells and hiPSC-CMs. Fig. S4 shows the relative expression of
fetal (slow skeletal) and adult (cardiac) troponin I isoforms in
hiPSC-CMs. Fig. S5 shows representative traces of hiPSC-CMs
spontaneously beating on 10-kPa polyacrylamide gels measured
by traction force microscopy. Fig. S6 shows comparison of the two
independently derived R92Q clones examined using traction force
microscopy, revealing no significant differences between the
clones. Table S1 displays quantitative reverse transcription PCR
(RT-qPCR) gene names and primers. Table S2 lists RT-qPCR
measurements of the expression of key calcium-handling genes.
Table S3 presents values from the electrophysiological experiments
in this study. Video 1 shows the displacement of beads by WT and
R92Q hiPSC-CMs contracting on a 10-kPa polyacrylamide gel. This
video was used to generate the representative traces in Fig. S5.

The initial biophysical insult of R92Q is increased thin filament
activation due to repositioning of tropomyosin along the
thin filament
To test whether the shift in calcium sensitivity can be explained
by a change in the distribution of positions assumed by tropomyosin along the thin filament (Fig. 3 A), we measured the
equilibrium constants that define the fraction of thin filament
regulatory units in each state (McKillop and Geeves, 1993;
Journal of General Physiology
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Barrick et al., 2019). The equilibrium constant between the
blocked and closed states, KB, was determined by rapidly mixing
fluorescently labeled regulated thin filaments together with
myosin and then measuring the rate of myosin binding (seen as
quenching of the fluorescence signal) in the presence and absence of calcium (see Materials and methods for details). At low
calcium, when tropomyosin is primarily in the blocked state, the
rate of myosin binding to the thin filament is slower than at high
calcium, when the blocked state is less populated. The ratio of
the rates of binding at low and high calcium were used to calculate KB (Eq. 1 and Fig. 3 B). As can be seen from the fluorescence transients, the rate of myosin binding to regulated thin
filaments is similar for the WT and R92Q mutant proteins at
high calcium (pCa 4); however, at low calcium (pCa 9), the rate
of binding for the mutant is much faster than for the WT, consistent with lower population of the blocked state. When we
calculate KB, we see that it is significantly larger in the mutant
compared with the WT (P = 0.003), meaning that population of
the more inhibitory blocked state is reduced while population of
the closed state is increased. The increased KB value means that,
at low calcium levels, the thin filament will be more activated in
the mutant, consistent with the in vitro motility measurements
(Fig. 2 A).
Next, we considered whether the mutation affects the equilibrium constant for the transitions between the closed and open
states, KT, or the equilibrium constant between the open and
myosin weakly bound states, Kw. To do this, we performed titrations of fluorescently labeled regulated thin filaments with
increasing concentrations of myosin and measured the
quenching of the fluorescence as the myosin binds to the
Clippinger et al.
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regulated thin filaments (Fig. 3 C). These data, analyzed using a
modification of the method of McKillop and Geeves (McKillop
and Geeves, 1993; Barrick et al., 2019), show that there are no
significant differences in KT between WT and R92Q (Fig. 3).
There is a small increase in Kw; however, its magnitude is insufficient to explain the shift in the in vitro motility assay. This
demonstrates that the primary molecular defect in R92Q is
partial activation of the thin filament at low calcium levels due
to reduced population of the inhibitory blocked state. Taken
together, our results demonstrate that the initial molecular
insult resulting from the R92Q mutation is decreased population of the thin filament blocked state, leading to increased thin
filament activation and myosin-driven force generation.
Computational modeling corroborates the assertion that
altered tropomyosin positioning with R92Q is sufficient to
explain the shift toward submaximal calcium activation
To model the effects of the initial molecular insult identified in
our biochemical studies, we utilized a widely used computational model of thin filament activation that was originally developed by Campbell et al. (Campbell et al., 2010). This model is
based on the McKillop and Geeves three-state formalism that
was also used to analyze our data (McKillop and Geeves, 1993). In
this model, the equilibrium constants for transitions between
thin filament states are inputted, and the model predicts several
parameters, including the force per sarcomere as a function of
calcium. When we used the default parameters of the model but
proportionally increase the value of KB to match the fractional
change seen in our biochemical experiments with the mutant
(Fig. 4 A), we find that this change alone is sufficient to produce
Journal of General Physiology
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Figure 2. R92Q does not change the rate of unloaded actomyosin dissociation or calcium binding affinity to troponin C. (A) In vitro motility assays
using cardiac myosin and reconstituted regulated thin filaments. The speed of motility was measured as a function of calcium. R92Q shows a shift toward
submaximal calcium activation. WT data are from Clippinger et al. (2019). Error bars represent SDs from three separate experiments. (B) The rate of ADP
release from myosin attached to regulated thin filaments was measured using stopped-flow kinetics (fluorescence transients are shown). Myosin bound to ADP
and pyrene-labeled regulated thin filaments was rapidly mixed with ATP, and the fluorescence increases as myosin dissociates from the thin filament. The rate
of actomyosin dissociation was unchanged by the R92Q mutation. WT data are from Clippinger et al. (2019). Curves show the average of five technical repeats.
(C) The affinity of calcium binding to the troponin complex. IAANS-labeled troponin C was reconstituted into regulated thin filaments. Titrations with increasing calcium were conducted, and there is no difference in calcium binding affinity between WT and R92Q. Error bars show the SD of five experiments.
Values derived from fits, standard errors in the fits, and P values are shown. P values were calculated using a two-tailed Student’s t test.
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the shift toward submaximal calcium activation observed in the
in vitro motility experiments (Fig. 2 A).
Generation of gene-edited stem cell–derived cardiomyocytes
To examine the effects of the R92Q mutation in human cells, we
used CRISPR-Cas9 to generate two independent hiPSC lines that
are homozygous for the R92Q mutation (Fig. S2). While there are
several splice isoforms of troponin T expressed during development, the primary isoform expressed in hiPSC-CMs is the
adult isoform (Cai et al., 2019). All of these isoforms contain R92,
so all of the troponin T expressed in the cell has the mutation
(Fig. S2). Homozygous lines were used to facilitate direct correlation of the molecular insult with alterations in cellular
function. Heterozygous lines would better mimic the disease
seen in humans but would contain complex mixtures of WT and
mutant proteins, confounding the correlation of the molecular and
cellular results. Both WT and R92Q hiPSCs were derived from the
same parent line and are therefore isogenic except for the mutation.
We previously showed, by whole-exome sequencing of the parent
line, that it has no known variants associated with cardiomyopathy
(Clippinger et al., 2019). Gene-edited hiPSCs are pluripotent, as
assessed by immunofluorescence (Fig. S3 A), and have normal
Clippinger et al.
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karyotypes (Fig. S3 B). hiPSCs were differentiated to hiPSC-CMs
through temporal modulation of WNT signaling (Lian et al.,
2012), and our efficiency of differentiation using this procedure is
>90% (Clippinger et al., 2019). Both WT and R92Q cells express
similar ratios of fetal (slow skeletal) to adult (cardiac) troponin I
isoforms (P = 0.49; Fig. S4).
R92Q hiPSC-CMs generate increased force, power, and
contraction speed compared with WT cells
To test whether R92Q hiPSC-CMs show the altered contractility
seen in some model systems, we measured the contractility of
single hiPSC-CMs using traction force microscopy. hiPSC-CMs
were seeded onto rectangular extracellular matrix patterns on
polyacrylamide hydrogels of physiological stiffness (10 kPa;
Clippinger et al., 2019). This patterning on physiological stiffness hydrogels promotes hiPSC-CM maturation and sarcomeric
alignment (Ribeiro et al., 2015). Patterned hiPSC-CMs show
sarcomeres that align preferentially along the long axis of the
cell (Fig. S3 B), and these cells contract primarily along that
single axis (Video 1). The force, speed of contraction, and power
were calculated from the displacement of beads embedded in the
hydrogel (Fig. S5; Ribeiro et al., 2017). Data were plotted as
Journal of General Physiology
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Figure 3. R92Q alters the positioning of tropomyosin along the thin filament. (A) Kinetic scheme for thin filament activation. (B) Measurement of the
equilibrium constant KB using stopped-flow kinetics methods (fluorescence transients are shown). Pyrene-labeled regulated thin filaments were rapidly mixed
with myosin at high (pCa 4) or low (pCa 9) calcium, and the rate of myosin binding was measured by quenching of the fluorescence. KB is calculated as
described in Materials and methods. The rate of myosin binding is similar for the WT and R92Q at pCa 4 but much faster for R92Q at pCa 9, consistent with
destabilization of the blocked state. KB for R92Q is significantly larger than the WT. (C) Measurement of the parameters KT and KW using equilibrium titrations
of myosin with regulated thin filaments. Fitting reveals no significant differences for R92Q for either KT or KW compared with the WT. WT data are from
Clippinger et al. (2019). Error bars show the standard deviation of five experiments. The average value, 95% confidence intervals calculated from bootstrapping,
and P values derived from the distribution of bootstrapped values are shown in the table.
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cumulative distributions of single cells to account for cell-to-cell
variability (Clippinger et al., 2019). R92Q hiPSC-CMs generate
more force and power and have a higher contractile speed
compared with the WT (Fig. 5). There were no significant differences observed between the two independently derived R92Q
clones that we examined (Fig. S6).
Intracellular calcium transients are reduced in R92Q cells
While the initial molecular insult driving the disease pathogenesis is alterations in tropomyosin positioning, which increases molecular contractility, changes in contractility can lead
to downstream activation of adaptive and maladaptive pathways. Previous studies using transgenic mice with troponin T
mutations also showed altered cardiomyocyte calcium handling
(Rice et al., 2010; Schober et al., 2012; Coppini et al., 2017;
Ferrantini et al., 2017; Robinson et al., 2018). To examine calcium
dynamics in hiPSC-CMs, cells were patterned onto rectangular
ECM patterns on 10-kPa hydrogels and loaded with the ratiometric fluorescent calcium indicator dye Fura Red. Line scans of
the fluorescence of spontaneously beating cells were collected at
1.9-ms intervals. As can be seen, hiPSC-CMs display welldefined calcium transients (Fig. 6 A); however, the amplitudes
of the transients are lower (P < 0.002) in R92Q (0.56 ± 0.13; n =
18) compared with WT (0.84 ± 0.11; n = 19) cells. Although the
low signal-to-noise ratio of the dye on the hydrogel substrate
precluded us from determining whether there were differences
in diastolic calcium, as has been reported previously (Schober
et al., 2012; Robinson et al., 2018), the data presented demonstrate that despite generating increased force, R92Q hiPSC-CMs
have reduced calcium transient amplitudes compared with
WT cells.
To see whether the reduced population of the blocked state,
observed in our molecular studies (Fig. 4 B), is sufficient to
explain the hypercontractility seen in cells despite the reduction
in calcium transient amplitude, we used the same computational
model described earlier to predict the force per sarcomere in
response to a calcium transient. In the modeling, the amplitude
Clippinger et al.
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of the calcium transient for R92Q was reduced to 67% of the
value seen in the WT, as observed in our cellular measurements
(Fig. 6 A). As above, we proportionally increased KB for the
mutant to match the relative difference seen in our biochemical
experiments. Consistent with our cellular experiments, the
model predicts that the mutant will generate more force in response to a calcium transient than the WT, despite having a
smaller amplitude calcium transient (Fig. 4 B). It should be noted
that hiPSC-CMs express complex mixtures of fetal and adult
protein isoforms and that, as a result, there could be some subtle
differences between the absolute forces predicted by the model,
which is based on the equilibrium constants measured for the
adult proteins, and the experimentally measured forces in
hiPSC-CMs.
R92Q cells show alterations in expression of
calcium-handling genes
The observed changes in calcium handling could come from a
variety of sources, including changes in transcription, protein
expression, and/or posttranslational modifications of proteins
that regulate calcium homeostasis. To explore a possible role for
transcriptional remodeling downstream of the initial molecular
insult, we performed RT-qPCR analyses of the expression of
transcripts encoded by key genes involved in the regulation of
calcium homeostasis in cardiomyocytes (Fig. 6). Specifically, we
examined the expression levels of transcripts encoding phospholamban (PLN), sarcoendoplasmic reticulum calcium-ATPase
(ATPA2), voltage-gated calcium channel subunits (CACNA1C,
CACNA1G, and CACNA1H), inositol triphosphate receptor (ITPR2),
calsequestrin (CASQ2), calcium-calmodulin dependent kinase
2 (CAMK2D), sodium-calcium exchanger (SLC8A1), and the ryanodine receptor (RYR2). We found marked up-regulation of
CASQ, CAMK2D, and SLC8A1 and down-regulation of CACNA1H in
R92Q compared with WT hiPSC-CMs (Figs. 6 B, Table S1, and
Table S2), demonstrating that the expression levels of key genes
associated with calcium handling are altered in R92Q hiPSCCMs.
Journal of General Physiology
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Figure 4. Computational modeling reveals that altered tropomyosin positioning is sufficient to explain the hypercontractility seen with R92Q. (A)
Using the computational model developed by Campbell et al. (2010) and the measured equilibrium constants for thin filament activation, the steady-state force
per sarcomere was calculated. Changing KB alone is sufficient to reproduce the shift toward submaximal calcium activation seen in the in vitro motility experiments (Fig. 2 A). (B) Using the same model, the equilibrium constants measured in vitro, and the calcium transients measured in hiPSC-CMs (Fig. 6 A), the
twitch force (solid line) in response to a calcium transient (dashed line) was calculated. Consistent with our cellular measurements, the simulations demonstrate that despite having a reduced calcium transient, R92Q produces a larger force in a twitch due to changes in tropomyosin positioning.
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R92Q cells show altered action potentials and reduced inward
calcium current densities
The observed reductions in the calcium transients observed
in spontaneously beating R92Q cells could reflect changes
in transmembrane calcium influx. To determine directly if
membrane excitability is altered in R92Q cells, we obtained
whole-cell current-clamp recordings of spontaneous action

potentials in WT and R92Q mutant hiPSC-CMs patterned
onto rectangular ECM patterns on 10-kPa hydrogels (Fig. 7, A
and B). Analyses of the data obtained in these experiments
revealed that the maximum diastolic potential (the most
negative membrane potential achieved between action potentials in spontaneously firing cells) is more depolarized in
R92Q hiPSC-CMs than in WT hiPSC-CMs (Fig. 7 B). In
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Figure 5. R92Q causes cellular hypercontractility in hiPSC-CMs. Single hiPSC-CMs were seeded on rectangular patterns on 10-kPa hydrogels for traction
force microscopy. (A–C) Cumulative distributions reveal that R92Q hiPSC-CMs have a greater total force (A), contraction speed (B), and contraction power (C)
compared with WT. WT data are from Clippinger et al. (2019). Values from the analysis, number of cells examined, 95% confidence intervals obtained from
bootstrapping, and P values derived from the distributions of bootstrapped values are listed in the table.

Figure 6. R92Q hiPSC-CMs show altered calcium transients and gene expression. (A) Representative fluorescence ratio traces showing calcium transients. Single hiPSC-CMs were seeded on rectangular patterns on 10 kPa hydrogels and loaded with the ratiometric calcium dye, Fura Red. R92Q hiPSC-CMs
calcium transients have lower amplitudes than the WT cells. (B) Expression of key calcium-handling genes measured using qPCR. Data show significant
increases in the expression of CASQ2, CAMK2D, and SLC8A1 and a decrease in CACNA1H. ΔCt values are shown in Table S2. Statistics were performed on the
ΔCt values; however, we show the log-fold changes. Red lines show the means, boxes show the quartiles, and error bars show the standard deviations. Data
shown reflect three biological replicates, each of which included three technical replicates. Asterisk denotes ΔCt values with P < 0.05 compared with the WT.
P values were calculated using a Mann–Whitney test.
Clippinger et al.
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addition, the frequency of spontaneous action potential firing is higher, upstroke velocities (i.e., the rate of membrane
depolarization) are lower, and action potential durations at
50% repolarization (APD50) are shorter in R92Q hiPSC-CMs
compared with WT cells (Fig. 7 B and Table S3).
To better understand the mechanisms contributing to the
reductions in the APD50 seen in spontaneously beating R92Q
cells, we examined the waveforms of evoked action potentials of
hiPSC-CMs hyperpolarized to a membrane potential of −80 mV.
Although similar hyperpolarizing currents were required to
render R92Q and WT hiPSC-CMs electrically silent and similar
currents were required to evoke action potentials in WT and
mutant cells, the durations of evoked action potentials are significantly shorter in R92Q cells than in WT cells (Fig. 7, C and D).
Additional voltage-clamp experiments were conducted to determine directly if voltage-gated inward calcium current densities
were altered in R92Q compared with WT cells. With outward potassium currents blocked, we recorded whole-cell voltage-gated
calcium currents evoked on membrane depolarization in WT and
R92Q hiPSC-CMs. As illustrated in Fig. 7 E, these experiments revealed that inward calcium current densities are markedly reduced
in R92Q compared with WT hiPSC-CMs (Fig. 7 F).
Clippinger et al.
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Discussion
Here, we elucidated the molecular and cellular consequences of
the R92Q mutation in troponin T. We show that the initial
molecular insult that drives disease pathogenesis is increased
thin filament activation at physiologically relevant micromolar
calcium levels due to destabilization of the tropomyosin blocked
state. We demonstrate computationally and experimentally that
this increased activation is consistent with the increased mechanical force produced by hiPSC-CMs. We show that altered
mechanical forces lead to downstream changes in the expression
of calcium-handling genes, altered calcium transients, and alterations in cellular electrophysiology. Taken together, our results highlight the role of mechanobiology in driving the early
disease pathogenesis.

Downloaded from http://rupress.org/jgp/article-pdf/153/5/e202012787/1413510/jgp_202012787.pdf by Washington University In St. Louis Libraries user on 01 May 2021

Figure 7. Spontaneous and evoked action potentials are altered in R92Q hiPSC-CMs and ICa densities are reduced. (A) Representative whole-cell
spontaneous action potentials recorded from WT and R92Q hiPSC-CMs are illustrated; dotted black lines indicate 0 mV. (B) Firing frequencies, maximum diastolic
potentials (MDP), maximum upstroke velocities (dV/dtmax) and APD50 measured in individual WT (n = 58) and R92Q (n = 29) hiPSC-CMs are plotted; mean values are also
indicated and are provided in Table S3. (C) Representative whole-cell action potential waveforms evoked from a hyperpolarized membrane potential, as described in
Materials and methods, in WT and R92Q cells are shown; dotted black lines indicate 0 mV. (D) dV/dtmax and APD50 values measured in individual WT (n = 58) and R92Q
(n = 29) cells are plotted; mean values are also indicated and are provided in Table S3. (E) Representative voltage-gated Ca2+ current (ICa) waveforms, elicited by voltage
steps to test potentials between −40 and +15 mV (in 5-mV increments) from a HP of −50 mV, in WT and R92Q hiPSC-CMs are shown. (F) Mean ± SEM peak ICa densities
in R92Q (n = 12) and WT (n = 15) hiPSC-CMs are plotted as a function of the test potential. Values in R92Q mutant cells are significantly different from those in WT cells at
the +, P < 0.05; ‡, P < 0.01; and *, P < 0.001 levels. P values were calculated using a two-tailed Student’s t test.

Defining the primary molecular driver of the
disease pathogenesis
Previous studies demonstrated that R92Q mutant protein is
expressed and properly integrated into sarcomeres, suggesting
that the driver of the disease is changes in protein function
rather than haploinsufficiency (Marian et al., 1997; Sweeney
et al., 1998; Tardiff et al., 1999; Yanaga et al., 1999). Our results
Journal of General Physiology
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R92L, leading to the suggestion that R92 is a hotspot for HCM
mutations. While there are no atomic-resolution structures of
this region of the thin filament, structural studies have shown
that troponin T plays a role in stabilizing the tropomyosin
blocked state (Tobacman et al., 2002; Johnson et al., 2019; Madan
et al., 2020). Molecular dynamics simulations demonstrated that
mutations at R92 can change the distance between troponin T
and tropomyosin (Manning et al., 2011), and biochemical experiments showed that R92L decreases the affinity of troponin
for tropomyosin (Gangadharan et al., 2017). These two mechanisms are not mutually exclusive, and we speculate that R92Q
reduces the coupling between troponin conformation and tropomyosin positioning, leading to destabilization of the blocked
state. It is worth noting that we have focused on the effects of a
troponin T mutation on calcium-based activation due to the
central role of troponin in calcium-dependent thin filament
regulation. Recent work has suggested that the N-terminal region of myosin binding protein C can play a role in activating the
thin filament in the C-zone (Mun et al., 2014; Risi et al., 2018;
Napierski et al., 2020). It will be interesting to investigate
whether the R92Q mutation also affects the interactions of
myosin binding protein C with the thin filament.
Recent studies of HCM-causing mutations in thick filament
proteins, including β-cardiac myosin, myosin binding protein C,
myosin regulatory light chain, and myosin essential light chain,
have demonstrated that many of these mutations disrupt the
autoinhibited super relaxed state of myosin, leading to the recruitment of more cross-bridges and thus to hypercontractility
(Spudich, 2015; McNamara et al., 2016; Alamo et al., 2017; Nag
et al., 2017; Adhikari et al., 2019; Sitbon et al., 2020). It has been
proposed that increased cross-bridge recruitment correlates
with the hyperdynamic cardiac function seen in HCM (Alamo
et al., 2017). Our studies with R92Q, a thin filament mutation,
demonstrate a similar net effect of increased cross-bridge recruitment at physiologically relevant calcium levels, suggesting
that altered recruitment of cross-bridges in HCM as a common
theme for both some thin and thick filament mutations.
It has been proposed that R92Q causes an increase in troponin C’s calcium affinity, which would affect the buffering of
calcium by myofilaments, disrupting calcium homeostasis
(Schober et al., 2012; Robinson et al., 2018). While our cellular
data reveal disrupted calcium homeostasis, our molecular experiments show no change in the affinity of calcium for R92Q
troponin, demonstrating that disrupted calcium homeostasis is
a downstream consequence of the initial molecular insult. Our
results are consistent with the notion that the development of
HCM correlates with changes in tension rather than calcium
handling (Davis et al., 2016).
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demonstrating that R92Q causes a shift toward submaximal
calcium activation (Fig. 2 A) are consistent with some (Morimoto
et al., 1998; Yanaga et al., 1999; Szczesna et al., 2000; Chandra
et al., 2001; Robinson et al., 2002; Ford et al., 2012), but not all
(Sweeney et al., 1998; Rust et al., 1999), previous measurements
in muscle fibers and biochemical assays using noncardiac protein isoforms. The shift toward submaximal calcium activation
could come from changes in actomyosin dissociation kinetics, the
affinity of calcium binding to troponin C, and/or the positioning
of tropomyosin along the thin filament (Fig. 1 B).
Our results demonstrate that R92Q does not affect the calcium binding affinity of troponin C or the kinetics of actomyosin
dissociation (Fig. 2); however, the mutation increases the equilibrium constant between the blocked and closed states (Fig. 3
B). This change favors the closed state over the blocked state,
lowering the energy barrier for thin filament activation at
physiologically relevant calcium concentrations (pCa 5–7). Our
computational modeling (Fig. 4) demonstrates that the increase
in this equilibrium constant is sufficient to explain the shift
toward submaximal calcium activation seen in our in vitro
motility measurements (Fig. 2 A). Our data demonstrate that the
initial insult that drives the early disease pathogenesis is reduced population of the inhibitory blocked position of tropomyosin at low calcium, which would lead to increased thin
filament activation.
The R92Q mutation has been studied in many model systems,
including quail myotubes (Sweeney et al., 1998), transfected rat
cardiomyocytes (Rust et al., 1999), skinned rabbit muscle fibers
(Morimoto et al., 1998), transgenic mice (Tardiff et al., 1999), and
transfected cat cardiomyocytes (Marian et al., 1997). While these
studies have greatly advanced our understanding of the mutation, they also demonstrated that the effects of the mutation
depend on the model system used. Studies using transgenic mice
demonstrated that disease presentation depends on whether
proteins with biophysical properties similar to human isoforms
are used (Ford et al., 2012). The use of all cardiac proteins with
biophysical properties similar to human proteins is important
for studies of thin filament mutations, since the activation of the
thin filament depends on both myosin and calcium binding
(Fig. 3 A). The most commonly used myosins in studies of R92Q
mutation have been murine ventricular myosin (MYH6–92%
sequence identity with human ventricular myosin) and rabbit
fast skeletal muscle myosin (MYH2–82% sequence identity
with human ventricular myosin), both of which have very different biophysical properties than human ventricular myosin
(VanBuren et al., 1995; Malmqvist et al., 2004; Debold et al.,
2007; Deacon et al., 2012). Our molecular studies used human
cardiac troponin and tropomyosin and porcine cardiac myosin
and actin. Porcine cardiac actin is identical in sequence to human cardiac actin. Porcine cardiac myosin (MYH7) is 98%
identical in sequence to the human isoform and displays biochemical kinetics, mechanical step sizes, and load-dependent
kinetics that are indistinguishable from human cardiac myosin
(Deacon et al., 2012; Greenberg et al., 2014; Sung et al., 2015).
Interestingly, the R92 residue is in the region of troponin T
that interacts with tropomyosin (Yamada et al., 2020). Two
other HCM mutations have been identified at R92, R92W, and

Connecting the molecular and cellular phenotypes in R92Q
R92Q hiPSC-CMs show both an increase in force production
(Fig. 5 A) and a reduction in the amplitude of the calcium
transient (Fig. 6 A). These seemingly conflicting findings can be
reconciled by our computational modeling (Fig. 4 B), which
predicts that the shift toward submaximal calcium activation
observed at the molecular scale can lead to cellular hypercontractility, despite the reduction in the amplitude of the
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et al., 2019). Hypercontractility of cardiomyocytes can impose
aberrant stretch on fibroblasts, activating the transition to myofibroblasts (Saucerman et al., 2019) and contributing to the
diffuse myocardial fibrosis frequently seen with HCM.
Implications for modeling and treating HCM
Modeling HCM is challenging since it is a complex disease where
different adaptive and maladaptive pathways are activated as
the disease progresses. Our goal was to connect the initial molecular insult with the early disease pathogenesis in human cells.
We therefore used genome-edited hiPSC-CMs, which are excellent tools for dissecting the early disease pathogenesis (Lam
and Wu, 2018). These experiments used isogenic cells, making it
easier to decipher the direct consequences of the mutation on a
controlled genetic background. R92Q hiPSC-CMs recapitulate
some important aspects of HCM-induced changes in contractility (Tardiff et al., 1999; Robinson et al., 2002; Ford et al., 2012),
altered electrophysiology (Coppini et al., 2017; Robinson et al.,
2018), and calcium dysfunction (Rice et al., 2010; Ferrantini
et al., 2017; Robinson et al., 2018) seen in other model systems.
It should be noted that hPSC-CMs have several important limitations (see limitations section below). Limitations aside, hiPSCCMs are powerful tools for studying the connection between the
initial molecular insult and the early disease pathogenesis in
human cells.
Our identification of altered cellular mechanics and downstream mechanobiological signaling pathways as key drivers of
the disease has important implications for therapeutics. There is
currently an outstanding need to develop new strategies to treat
HCM. Our results suggest that targeting mechanobiological signaling pathways in cardiomyocytes could be useful for treating
some forms of HCM.
We believe that cardiomyopathies are excellent candidates
for a precision medicine approach (McNally and Mestroni, 2017;
Fatkin et al., 2019; Lavine and Greenberg, 2020; Greenberg and
Tardiff, 2021). Recently, there was a report of a HCM mutation
in α-actinin linked to action potential prolongation attributed to
increased calcium current density (Prondzynski et al., 2019), and
the patient harboring this mutation was successfully treated
with the L-type calcium channel blocker diltiazem. In R92Q, we
observed a reduction in the calcium current density (Fig. 7), and
therefore, a different therapeutic strategy would be necessary.
Similarly, hiPSC-CMs harboring an HCM-linked mutation in
troponin T, I79N, display changes in the action potential durations due to altered sodium–calcium exchanger function. Again,
the cellular mechanism is distinct from that observed for R92Q,
which is associated with changes in the inward calcium current
density, potentially suggesting different therapeutic strategies
(Wang et al., 2017; Wang et al., 2018). The marked differences
between the functional effects of different HCM mutations
highlight the need to understand the underlying derangements
in molecular and cellular function when designing therapies.
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calcium transient. This hypercontractility occurs at physiologically relevant (micromolar) concentrations of calcium (Bers,
2002). Therefore, the observed cellular hypercontractility is
consistent with the proposed molecular mechanism.
At the cellular level, we see disrupted calcium homeostasis
with R92Q, which is downstream of the initial contractile insult.
Calcium homeostasis in the myocardium is a complicated process
that depends on many factors, including gene expression and
posttranslational modifications of signaling and contractile proteins (Bers, 2002). While a complete dissection of this mechanism
is beyond the scope of the current study, our results provide insights into potential transcriptional mechanisms. We observed
changes in the expression of several genes involved in calcium
handling (Fig. 6 B), including calsequestrin (CASQ2), calciumcalmodulin kinase (CAMK2D), the sodium-calcium exchanger
(SLC8A1), and a voltage-gated calcium channel subunit (CACNA1H).
Interestingly, overexpression of CASQ2 or CAMK2D in transgenic
mice causes heart failure and arrhythmogenesis (Sato et al., 1998;
Zhang et al., 2003). While we recognize that changes in transcript
expression do not always correlate with protein function, our data
demonstrate that altered mechanics at the molecular level can
drive changes in gene expression, showing a mechanobiological
link between these processes in HCM. It is worth noting that some
of the differentially expressed calcium-handling genes observed
here in human cells are different from observations in the R92Q
mouse model, which may be due to species differences (Coppini
et al., 2017; Chowdhury et al., 2020). Interestingly, in mice, ablation of PLN can rescue the HCM phenotype, and it will be interesting to see whether similar results are observed in human cells
(Chowdhury et al., 2020).
Our single-cell electrophysiological experiments reveal that
action potential durations are shorter in R92Q, compared with
WT cells, due in part to reduced inward L-type calcium current
densities (Fig. 7). These changes would be expected to be arrhythmogenic and could contribute to the increased incidence of
arrhythmias and sudden death in individuals harboring the
mutation. We observe normal expression levels of the transcripts encoding L-type channel subunits, and therefore, the
reduced current density could be due to alterations in signaling
pathways and/or posttranslational modifications of channel
subunits. The reduced inward calcium current densities (Fig. 7)
would be expected to reduce calcium-induced calcium release
from intracellular calcium stores, potentially contributing to the
reductions in calcium transient amplitudes (Fig. 6 A).
Based on our observation that molecular hypercontractility
drives downstream changes in cellular calcium handling and
electrophysiology, we propose that mutation-induced changes in
cellular tension alter mechanosensitive signaling pathways in
cardiomyocytes (Saucerman et al., 2019). Consistent with this
idea, we recently demonstrated that a dilated cardiomyopathy
mutation in troponin T, ΔK210, affects molecular tension and
mechanosensing, which helps to drive the disease progression
(Clippinger et al., 2019). Similarly, increases in cardiac tension
from external sources, including hypertensive disease and aortic
stenosis, promote pathological hypertrophy. Deciphering the
mechanobiological pathways in cardiomyocytes is an active field
of research (Prosser et al., 2011; Robison et al., 2016; Saucerman

Limitations
In our molecular studies, we were interested in uncovering the
initial molecular insult of the R92Q mutation in troponin T that
drives the early disease pathogenesis. As such, we focused on the
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Conclusions
We demonstrate that the initial insult of the R92Q mutation in
troponin T is molecular hypercontractility at physiologically
relevant calcium concentrations, which leads to alterations in
mechanobiological signaling pathways that regulate calcium
homeostasis, gene expression, and cellular electrophysiology.
Taken together, our results demonstrate that mechanobiological
adaptations are important in the early disease pathogenesis, and
they suggest that targeting these pathways could open new
avenues for treating HCM.
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Figure S1. Affinity of calcium binding to the troponin complex at 20°C and 37°C. IAANS-labeled troponin C was reconstituted into regulated thin filaments. Titrations with increasing calcium were conducted. Error bars show the SD of greater than or equal to three experiments. Values derived from fits,
standard errors in the fits, and P values are shown. P values were calculated using a two-tailed Student’s t test.
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Figure S2. Generation of gene-edited hiPSC-CMs. (A) Sequence alignment of troponin T splice isoforms expressed in humans reveals that all isoforms
contain the R92 residue. (B) CRISPR-Cas9 targeting of R92Q in troponin T. The R92Q mutation was added via homology-directed repair. The gRNA sequence
for targeting was 59-CCTTCTCCATGCGCTTCCGGNGG-39. From our screen, 21% of the cells were homozygous for the R92Q mutation (CGG→CAA). (C) Karyotyping of R92Q gene-edited cells reveals a normal karyotype.
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Figure S3. Immunofluorescence images of stem cells and hiPSC-CMs. (A) Pluripotency staining of R92Q cells. R92Q gene-edited cells are pluripotent as
assessed by immunofluorescence staining for the markers SSEA4, OCT4, SOX2, and TRA-1-60. (B) Projections of hiPSC-CMs on glass stained for α-actinin to
mark the sarcomeric Z-discs.
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Figure S4. Relative expression of fetal (slow skeletal) and adult (cardiac) troponin I isoforms in hiPSC-CMs. (A) Western blot showing the expression of
the fetal isoform of troponin I (slow skeletal troponin I [ssTnI]). Shown are four lysates from WT cells (W1, W2, W3, and W4) and four lysates from R92Q cells
(R1, R2, R3, and R4). GAPDH is used as a loading control. (B) Western blot on a separate membrane showing the expression of the adult isoform of troponin I
(cardiac troponin I [cTnI]). Shown are four lysates from WT cells (W1, W2, W3, and W4) and four lysates from R92Q cells (R1, R2, R3, and R4). GAPDH is used as
a loading control. (C) Quantification of the ratio of ssTnI/cTnI was determined by densitometry. The TnI/GAPDH ratio was calculated for both ssTnI and cTnI
and then divided to get the ratio. These is no difference in the ratio (ns, not significant [P = 0.49] by Mann–Whitney test).
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Figure S5. Representative traces of hiPSC-CMs spontaneously beating on 10-kPa polyacrylamide gels measured by traction force microscopy.
Plotted are the force of contraction, the velocity, and the power output. Positive values denote shortening and negative values denote lengthening.
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Figure S6. Comparison of the two independently derived R92Q clones examined using traction force microscopy reveals no significant differences
between the clones. Cumulative distributions showing the force, speed, and power of contraction. P values are calculated from a Mann–Whitney U test.
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Video 1. Displacement of beads by WT (gray) and R92Q (red) hiPSC-CMs contracting on a 10 kPa polyacrylamide gel. Videos were recorded at 30
frames/s using a spinning disc confocal microscope (Nikon). The cell, which is not visible, is on a rectangular pattern of Matrigel with a 7:1 aspect ratio. The
displacement of the beads was tracked as a function of time. Note that the two cells shown are not on the same slide/hydrogel; rather, we have merged two
videos to facilitate direct visual comparison of the contractility in WT and mutant cells. As is evident in the video, force is generated primarily along the long
axis of the cells. These videos were used to generate the representative traces in Fig. S5.
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Three supplemental tables are provided online. Table S1 displays the RT-qPCR gene names and primers used in this study. Table S2
lists the RT-qPCR measurements of the expression of key calcium-handling genes. Table S3 provides the values from this study’s
electrophysiological experiments.
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